Subscription Center
Jan 9, 2009 | 1
Some consumer groups are bleating over the prospect of a new anti-clotting drug made from genetically modified goats.
An advisory committee to the Food and Drug Administration (FDA) is meeting today to discuss whether to recommend approval of ATryn, a med made from the milk of goats engineered to produce copious amounts of the blood-thinning protein antithrombin. This is the first time an FDA panel is considering a commercial food or drug product produced from a genetically altered animal.
(See a story from our September 2006 issue for more on ATryn.)
ATryn, manufactured by Massachusetts-based biotech GTC Biotherapeutics, is not being mulled as a sub for traditional blood thinners, but rather for use during surgery or childbirth for the one in 5,000 Americans with antithrombin deficiencies at increased risk of developing potentially fatal blood clots in their lungs or brains, the Associated Press says.
See what we're tweeting about
BoraZ Journal editors and their excuses https://t.co/kbq3k4paZP BoraZ Obedient Media: Press release sees missing link in space. Hmm, a weak metaphor. Cliche too. Most use it anyway. http://t.co/NcKB5ygIRB
philipyam @dcastelvecchi @Yahoo It's annoyingly hidden in your name, forcing you to hover over it to see. But still not as bad as Gmail's
Deadline: Jul 15 2013
Reward: $5,000 USD
SciBX: Science-Business eXchange, a joint publication from the makers
Deadline: Jun 30 2013
Reward: $1,000,000 USD
This is a Reduction-to-Practice Challenge that requires written documentation and&
Powered By: 
YES! Send me a free issue of Scientific American with no obligation to continue the subscription. If I like it, I will be billed for the one-year subscription.
